Macular Degeneration
Conditions
Keywords
wAMD, anti-VEGF
Brief summary
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011. Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be documented. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
Interventions
DRUGRanibizumab
Patients with wet AMD treated with ranibizumab as prescribed by physician
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of wet Age-related Macular Degeneration * Start of anti-VEGF therapy with ranibizumab (Lucentis) between January 1, 2009 and December 31, 2009 * Informed consent form signed
Exclusion criteria
\- Participation in an investigational study during anti-VEGF therapy (from start up to December 31, 2011) that involved treatment with any drug or device
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard | Baseline and 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Mean time from first clinical presentation to diagnosis | Baseline |
| Mean time from diagnosis to treatment | Time from diagnosis to treatment: Up to 24 months |
| Mean time from diagnosis to end of follow-up | Time from diagnosis to end of follow-up: up to 48 months |
| Demographic characteristics of patients included in the study (Age, Sex, Race) | Baseline |
| Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT) | Baseline and 24 months |
| Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA) | Baseline and 24 months |
| Average number of treatments given from diagnosis to end of follow-up | After 24 months |
| Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart | Baseline and 24 months |
Countries
Portugal
Outcome results
None listed